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Editor
Prophylactic Use of an Implantable Cardioverter-Defibrillator 
After Acute Myocardial Infarction
Abstract. Background. Implantable 
cardioverter-defibrillator (ICD) thera-
py has been shown to improve survival 
in patients with various heart condi-
tions who are at high risk for ven-
tricular arrhythmias. Whether benefit 
occurs in patients early after myocar-
dial infarction is unknown. 
Methods. We conducted the 
Defibrillator in Acute Myocardial 
Infarction Trial (DINAMIT), a ran-
domized, open-label comparison of 
ICD therapy (in 332 patients) and no 
ICD therapy (in 342 patients) 6–40 
days after myocardial infarction. We 
enrolled patients who had reduced left 
ventricular function (left ventricular 
ejection fraction, 0.35 or less) and 
impaired cardiac autonomic function 
(manifested as depressed heart-rate 
variability or an elevated average 24-
hour heart rate on Holter monitoring). 
The primary outcome was mortality 
from any cause. Death from arrhythmia 
was a predefined secondary outcome. 
Results. During a mean (± SD) 
follow-up period of 30±13 months, 
there was no difference in overall 
mortality between the two treatment 
groups: of the 120 patients who died, 
62 were in the ICD group and 58 in 
the control group (hazard ratio for 
death in the ICD group, 1.08; 95% 
confidence interval [CI], 0.76–1.55; 
p=0.66). There were 12 deaths due 
to arrhythmia in the ICD group, as 
compared with 29 in the control group 
(hazard ratio in the ICD group, 0.42; 
95% CI, 0.22–0.83; p=0.009). In con-
trast, there were 50 deaths from non-
arrhythmic causes in the ICD group 
and 29 in the control group (hazard 
ratio in the ICD group, 1.75; 95% CI, 
1.11–2.76; p=0.02). 
Conclusions. Prophylactic ICD 
therapy does not reduce overall mor-
tality in high-risk patients who have 
recently had a myocardial infarction. 
Although ICD therapy was associ-
ated with a reduction in the rate of 
death due to arrhythmia, that was 
offset by an increase in the rate of 
death from nonarrhythmic causes.—
Hohnloser SH, Kuck KH, Dorian P, 
et al. Prophylactic use of an implant-
able cardioverter-defibrillator after acute 
myocardial infarction. N Engl J Med. 
2004;351:2481–2488.
Comment. We review the Sudden 
Cardiac Death in Heart Failure Trial 
(SCD-HeFT) below, so it is timely to 
review another important trial: the 
DINAMIT—the first randomized con-
trolled study to assess the impact of 
implantable cardioverter-defibrillator 
(ICD therapy very early after myocar-
dial infarction (MI). DINAMIT was 
designed to test whether prophylactic 
implantation of an ICD would reduce 
mortality in survivors of a recent MI 
who are at high risk for ventricu-
lar arrhythmias. Patients aged 18–80 
years were enrolled if they recently 
had an MI (6–40 days previously) and 
if they had a left ventricular ejection 
fraction of 35% or less. This trial ran-
domized 674 patients within 40 days 
of an acute MI to current standard 
medical therapy with or without an 
ICD and followed them for a mean of 
2.5 years. Three hundred thirty-two 
patients were randomly assigned to 
the ICD group and 342 to the control 
group. The mean left ventricular ejec-
tion fraction was 28%. The average 
time from MI to randomization was 
18 days and was similar in the two 
groups. There was excellent adher-
ence to optimal medical therapy in 
both groups, which included angio-
tensin-converting enzyme inhibitors, 
β blockers, aspirin, and lipid-lowering 
drugs. Patients who were random-
ly assigned to receive an ICD were 
required to undergo implantation of a 
market-approved, single-chamber ICD 
(St. Jude Medical, Sunnyvale, CA) 
within 1 week after randomization. 
The primary outcome in DINAMIT 
was death from any cause. Death due 
to cardiac arrhythmia was the second-
ary outcome. There was no difference 
in overall mortality between the two 
groups. Of the 120 who died, 62 were 
in the ICD group and 58 in the control 
group (hazard ratio for death in the 
ICD group, 1.08; p=0.66). There were 
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12 deaths due to arrhythmia in the 
ICD group compared with 29 among 
controls (hazard ratio for the ICD 
group, 0.42; p=0.009). In contrast, 
there were 50 deaths from nonar-
rhythmic causes in the ICD group, but 
only 29 in the controls (hazard ratio 
for the ICD group, 1.75; p=0.02). In 
essence, in DINAMIT, the reduction 
in the rate of arrhythmia-related death 
was very similar to that observed in 
previous trials of  ICD therapy. 
In contrast to the previous trials, 
however, DINAMIT revealed a statis-
tically significant increase in the rate 
of death from nonarrhythmic causes 
among patients assigned to receive an 
ICD. Most of these deaths (78%) were 
cardiovascular in nature. It appears that 
in DINAMIT, as in previous trials of 
ICD therapy, the ICD prevented death 
from ventricular fibrillation; however, 
preventing death from ventricular 
fibrillation did not reduce overall mor-
tality in these patients. The reason 
for the unexpected and unprecedented 
increase in mortality from causes other 
than arrhythmia in patients assigned 
to receive an ICD is not clear. There 
was no sign of an increased rate of 
death in association with the surgi-
cal procedure or complications with 
the use of the ICD. It is unlikely that 
the increased rate of deaths from car-
diac, nonarrhythmic causes was due to 
excessive pacing because the backup 
pacing was programmed at a very low 
rate in almost all the patients in the 
ICD group. Regardless of the plausible 
mechanism, this important clinical trial 
identifies a group of patients with risk 
factors for sudden death from cardiac 
causes in whom ICD therapy may not 
provide a survival benefit. 
DINAMIT suggests that patients 
with a recent MI and acute-onset left 
ventricular systolic dysfunction (left 
ventricular ejection fraction even less 
than 35%) do not benefit from ICDs 
for overall survival. One should wait 
until everything is stabilized following 
an MI—a period of perhaps 6 weeks—
before prophylactic implantation of an 
ICD is considered.
Amiodarone or an Implantable Cardioverter-Defibrillator for 
Congestive Heart Failure
Abstract. Background. Sudden death 
from cardiac causes remains a lead-
ing cause of death among patients 
with congestive heart failure (CHF). 
Treatment with amiodarone or an 
implantable cardioverter-defibrillator 
(ICD) has been proposed to improve 
the prognosis in such patients. 
Methods. We randomly assigned 
2521 patients with New York Heart 
Association (NYHA) class II or III 
CHF and a left ventricular ejection 
fraction (LVEF) of 35% or less to con-
ventional therapy for CHF plus placebo 
(847 patients), conventional therapy 
plus amiodarone (845 patients), or con-
ventional therapy plus a conservatively 
programmed, shock-only, single-lead 
ICD (829 patients). Placebo and amio-
darone were administered in a double-
blind fashion. The primary end point 
was death from any cause. 
Results. The median LVEF in 
patients was 25%. Seventy percent were 
in NYHA class II, and 30%  were in 
class III CHF. The cause of CHF was 
ischemic in 52% and nonischemic in 
48%. The median follow-up was 45.5 
months. There were  244 deaths (29%) 
in the placebo group, 240 (28%) in the 
amiodarone group, and 182 (22%) in 
the ICD group. As compared with pla-
cebo, amiodarone was associated with 
a similar risk of death (hazard ratio, 
1.06; 97.5% confidence interval [CI], 
0.86–1.30; p=0.53) and ICD therapy 
was associated with a decreased risk 
of death of 23% (hazard ratio, 0.77; 
97.5% CI, 0.62–0.96; p=0.007) and 
an absolute decrease in mortality of 
7.2 percentage points after 5 years in 
the overall population. Results did not 
vary according to either ischemic or 
nonischemic causes of CHF, but they 
did vary according to the NYHA class. 
Conclusions. In patients with NYHA 
class II or III CHF and LVEF of 35% 
or less, amiodarone has no favorable 
effect on survival, whereas single-lead, 
shock-only ICD therapy reduces over-
all mortality by 23%.—Bardy GH, Lee 
KL, Mark DB, et al. Amiodarone or an 
implantable cardioverter-defibrillator for 
congestive heart failure. N Engl J Med. 
2005;352:225–237.
Comment. This trial was initially pre-
sented at the American College of 
Cardiology 2004 Scientific Sessions but 
was published only recently. It is one of 
the major trials which will define the 
future of heart failure (HF) therapy. 
The trial randomized 2521 patients 
with New York Heart Association class 
II or III CHF and LVEF ≤35% to 
receive a single-lead ventricular ICD 
programmed to shock-only mode or 
either amiodarone or a matching place-
bo, with the latter two arms conducted 
double blind. It is worth noting that 
this trial recruited both ischemic and 
nonischemic HF patients. All patients 
were on “state-of-the-art background 
medical therapy” for HF that over-
whelmingly included β blockers and 
either angiotensin-converting enzyme 
inhibitors or angiotensin receptor block-
ers. Patients assigned to amiodarone or 
matching placebo began therapy as out-
patients immediately after randomiza-
tion. Patients assigned to ICD therapy 
received their device over a median of 
3 days after randomization. At baseline, 
the median LVEF of patients was 25%; 
70% had New York Heart Association 
class II HF, and 30% had class III HF. 
The median follow-up for all surviving 
patients was 45.5 months. All surviv-
ing patients were followed for at least 2 
years. The primary end point of the trial 
was death from any cause. A total of 666 
patients died: 244 (29%) in the placebo 
group; 240 (28%) in the amiodarone 
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group; and 182 (22%) in the ICD 
group. As compared with placebo, ami-
odarone therapy was associated with 
a similar risk of death (hazard ratio, 
1.06; 97.5% CI, 0.86–1.30; p=0.53) 
and ICD therapy was associated with 
a decreased risk of death (hazard ratio, 
0.77; 97.5% CI, 0.62–0.96; p=0.007). 
The significant ICD survival benefit 
was independent of whether HF was 
ischemic or nonischemic in origin. 
The authors deduced two principal 
findings. First, therapy with a conser-
vatively programmed, shock-only ICD 
significantly decreased the relative risk 
of death by 23%, resulting in an abso-
lute reduction of 7.2 percentage points 
at 5 years among patients with HF who 
received state-of-the-art background 
medical therapy, and the benefit did 
not vary according to the cause of HF. 
Second, amiodarone had no beneficial 
effect on survival, despite the use of 
appropriate dosage and reasonable com-
pliance rates over longer periods than in 
other placebo-controlled trials. In this 
trial, single-lead ICDs had a 5% rate of 
acute device-related complications and 
a 9% rate of chronic complications. 
Overall, this is a great trial which 
was well done. It is very important to 
emphasize, however, that this trial deals 
with patients who had chronic HF and 
were treated well with current standard 
medical therapy for HF. Patients present-
ing for the first time with HF and a low 
LVEF should not receive ICDs before 
being treated with standard HF medi-
cal therapy. So, in essence, physicians 
should achieve maximal medical man-
agement before proceeding with ICD. 
In patients with New York Heart 
Association class II or III HF and 
LVEF of 35% or less, amiodarone 
has no favorable effect on survival. 
In contrast, shock-only ICD therapy 
improves survival beyond the improve-
ment afforded by the current standard 
HF therapy. On a population basis, we 
will save one life for every 14 patients 
treated with ICD for 5 years. 
Tepper (continued from page 158)
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